AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS

Background: Ixekizumab (IXE), a high-affinity monoclonal antibody targeting IL-17A, has demonstrated superiority in achieving the combined endpoint of ACR50 and PASI100 at week (Wk) 24 compared to adalimumab (ADA) SPIRIT-H2H trial [1]. In this analysis, we looked efficacy responses individual patient (pt) level assess consistency over time each visit. Objectives: To determine American College Rheumatology 50% (ACR50) response Disease Activity psoriatic arthritis (PsA) (DAPSA) pts treated with IXE describe visit from Wk through 52. Methods: This post-hoc analysis used data ( NCT03151551 ), phase3b/4 randomised, open-label parallel-group study between ADA. Pts were randomised receive either 80 mg, every 4 Wks (IXE Q4W)) or ADA 40 2 (ADA Q2W)). The proportion (%) intent-to-treat population who achieved endpoint, DAPSA≤14, post-baseline out 52 was assessed. Nine active psoriasis body surface area (BSA) ≥3% assessed as PASI=0 baseline, medical inconsistency that resolved using judgement. These considered responders if BSA=0 post baseline visits. Results: A total 566 patients enrolled received (N=283) (N=283). Of 143 24, 65% (N=93) maintained total, 83% (N=118) achievers some (18% (N=25)) fluctuations, ACR20 (Figure 1). 132 55% (N=72) 80% (N=105) (25% (N=33)) fluctuations (Table Furthermore, the174 low DA (DAPSA≤14) 68% (N=119) 82% (N=142) (13% (N=23)) moderate 1B). 171 24; 57% (N=97) 77% (N=131) (20% (N=34)) Conclusion: demonstrates numerically higher versus show response, measured by DAPSA responses, for pt level. References: [1]Mease et al. Ann Rheum Dis. 2020;79(1):123-131 Table 1. Consistency effect PsA. Q4W Q2W Response, % (n) DAPSA≤14 DA, Patients 51% (143) 61% (174) 47% (132) 60% (171) Achieved fluctuations* (105) (131) Maintained (72) (97) Had 18% (N=25) 13% (N=23) 25% (33) 20% (34) * ACR20, disease activity. Figure Heatmap diagram describing PsA (low activity) 24. Acknowledgements : Edel Hughes, an employee Eli Lilly Company, provided editorial writing support. Disclosure Interests: Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Lilly, Janssen, Medac, Novartis, Pfizer, UCB., Consultant of: Boehringer Ingelheim, Bristol-Myers Squibb, UCB, Grant/research support from: David Sandoval Shareholder & Employee Rebecca Bolce Chen-Yen Lin Keri Stenger Aubrey Trevelin Sprabery Company; Johnson Johnson, Arthur Kavanaugh BMS, Janssen.